Development of a5 nicotinic receptor agonists for smoking cessation
Award amount
$793,191Program and phase
SBIR · Phase IIAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- OPHIDION, INC.
- Proposal award date
- 2015-05-01
- Contract end date
- 2018-04-30
- UEI
- NNGSPLRM7DL6
- Solicitation number
- PA14-071
- Topic code
- R44
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- In vivo and in vitro tools to target CHRNA5 for smoking cessation.
- Biologic approach to targeting a nicotinic receptor accessory molecule for cognit
- Improved Cell Line and Assay Development of Nicotinic Receptor Complexes for HTS
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Chikungunya Recombinant Subunit Vaccine
- Multiplexed Assay for Point-of-Care UTI Diagnosis (ID/AMR)
- Development of World's First Fully Human Broad Spectrum Anti-Snake Venom
- Hybrid ELISA: Simple and specific one-tier assay for Lyme disease
- A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance
Research funding history
4 SBIR/STTR records share this UEI (2008–2015). Reported award amounts total $2,245,584. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services